Amneal Pharmaceuticals (NASDAQ:AMRX) Upgraded at StockNews.com

StockNews.com upgraded shares of Amneal Pharmaceuticals (NASDAQ:AMRX) from a buy rating to a strong-buy rating in a report released on Monday morning.

Several other equities research analysts have also issued reports on the stock. Truist Financial increased their target price on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Wednesday, October 2nd. Piper Sandler increased their price target on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday. Barclays boosted their price objective on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a research report on Tuesday, August 13th. Finally, JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 target price on the stock in a research report on Friday, September 6th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $10.00.

Amneal Pharmaceuticals Trading Down 2.4 %

AMRX opened at $9.03 on Monday. The firm has a fifty day moving average price of $8.55 and a 200 day moving average price of $7.61. Amneal Pharmaceuticals has a 1 year low of $4.16 and a 1 year high of $9.48.

Institutional Investors Weigh In On Amneal Pharmaceuticals

A number of large investors have recently modified their holdings of AMRX. Vanguard Group Inc. grew its stake in Amneal Pharmaceuticals by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 13,728,233 shares of the company’s stock valued at $83,193,000 after acquiring an additional 85,846 shares in the last quarter. Hillsdale Investment Management Inc. increased its holdings in shares of Amneal Pharmaceuticals by 19.7% in the first quarter. Hillsdale Investment Management Inc. now owns 699,719 shares of the company’s stock valued at $4,240,000 after purchasing an additional 115,100 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Amneal Pharmaceuticals by 20.7% during the second quarter. Bank of New York Mellon Corp now owns 751,403 shares of the company’s stock worth $4,771,000 after buying an additional 128,772 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its stake in Amneal Pharmaceuticals by 417.8% during the first quarter. CANADA LIFE ASSURANCE Co now owns 36,106 shares of the company’s stock worth $218,000 after buying an additional 29,133 shares during the last quarter. Finally, Acadian Asset Management LLC grew its holdings in Amneal Pharmaceuticals by 701.8% in the 2nd quarter. Acadian Asset Management LLC now owns 811,853 shares of the company’s stock valued at $5,148,000 after buying an additional 710,598 shares in the last quarter. Hedge funds and other institutional investors own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.